Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Cocrystal Pharma Inc (COCP)

Cocrystal Pharma Inc (COCP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Cocrystal Pharma to Present Data from Phase 1 Study of First-in-Class Norovirus Protease Inhibitor CDI-988 at the 9th International Calicivirus Conference GlobeNewswire - Thu Jul 10, 7:00AM CDT

COCP : 1.8000 (+14.65%)
Cocrystal Pharma’s Novel Norovirus Antiviral to be Presented at Department of Defense Medical Conference GlobeNewswire - Thu Jun 5, 7:00AM CDT

COCP : 1.8000 (+14.65%)
Cocrystal Pharma’s Investigational Drug Candidate CC-42344 Demonstrates Strong Antiviral Potency Against the 2024 Highly Pathogenic H5N1 Avian Influenza Strain GlobeNewswire - Thu May 29, 7:00AM CDT

COCP : 1.8000 (+14.65%)
Cocrystal Pharma to Participate in Noble Capital Markets’ 2025 Emerging Growth Virtual Equity Conference GlobeNewswire - Wed May 28, 7:00AM CDT

COCP : 1.8000 (+14.65%)
Cocrystal Pharma Reports First Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs GlobeNewswire - Thu May 15, 7:00AM CDT

COCP : 1.8000 (+14.65%)
Cocrystal Pharma’s Norovirus Oral Antiviral Candidate Demonstrates Potent Activity Against the Emerging GII.17 Variants GlobeNewswire - Thu Apr 24, 7:00AM CDT

COCP : 1.8000 (+14.65%)
Cocrystal Pharma to Present at Life Science Innovation Northwest 2025 Conference GlobeNewswire - Wed Apr 16, 7:00AM CDT

COCP : 1.8000 (+14.65%)
Cocrystal Pharma Reports 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs GlobeNewswire - Mon Mar 31, 7:00AM CDT

COCP : 1.8000 (+14.65%)
Cocrystal Pharma to Participate in a Fireside Chat at the Zacks SCR Life Sciences Virtual Investor Forum on March 13, 2025 GlobeNewswire - Thu Mar 6, 7:00AM CST

COCP : 1.8000 (+14.65%)
Cocrystal Pharma Reports Phase 1 Results with Oral, Broad-Acting Antiviral Drug CDI-988 for Prophylaxis and Treatment of Norovirus, Coronaviruses and Other Viral Infections GlobeNewswire - Wed Jan 8, 7:00AM CST

COCP : 1.8000 (+14.65%)

Barchart Exclusives

Gold's Bull Run: Seasonal Strength Meets Conflicting COT Report—Are You In? Barchart - Sat Jul 12, 2:47PM CDT
Gold's all-time high $3,509.9! Central banks bought big, but the COT report waves a red flag. Seasonal gains await—Market players, read or regret! Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot